- Reducing investments in certain non-core professional audio communications product lines;
- Aggressively transferring specific product lines from Singapore to IntriCon’s lower-cost manufacturing facility in Batam, Indonesia;
- Reducing global administrative and support workforce;
- Transferring the medical coil business from the company’s Maine facility to Minnesota to better leverage existing manufacturing capacity, and exploring alternatives for the remaining security and microphone business, including possible sale; and
- Adding experienced professionals in value hearing health and also focusing more resources in medical biotelemetry.
Additionally, IntriCon will classify its Maine operations, which include the company’s security, microphone and receivers businesses, as discontinued operations for financial reporting purposes. Certain Singapore assets that support the microphone and receiver product lines also will be classified as discontinued.The company expects to achieve an additional $1.0 million in annual cost savings by the end of 2013, through the actions detailed above. Combined, IntriCon anticipates total annual cost savings of approximately $3.0 million. The company expects to incur total cash charges ranging from $200,000 to $250,000, or $0.04 per share, related to its restructuring initiatives for the remainder of the 2013 fiscal year. “Change of this nature is hard, but necessary, for the health of IntriCon,” said Gorder. “By right-sizing our organization, and better leveraging our existing resources, we’ll be able to aggressively drive our two largest growth opportunities—which we expect will strengthen in the second half of the year.” Gorder said the company can accommodate revenue growth and deliver profitability through the capacity at its existing facilities. IntriCon plans to announce second-quarter results in the first half of August and will provide additional information on the restructuring at that time. About IntriCon Corporation Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com. Forward-Looking Statements Statements made in this release and in IntriCon’s other public filings and releases that are not historical facts or that include forward-looking terminology are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon’s control, and may cause IntriCon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.